SHARE

ASK: Legal support – COVID-19 prognosis tool

30th April 2020

Online evidence synthesis platform and risk assessment tool

Epidy Health Research Ltd is looking for support with GDPR.

Epidy Health Research Ltd has just launched their online evidence synthesis platform and risk assessment tool for factors associated with the development and prognosis of COVID-19.

The organisation is requesting:

  • Legal support – to help ensure their platform is GDPR compliant.

More information on the solution:

Online evidence synthesis platform

The evidence synthesis platform has been created for scientists to access up-to-date and summarised information on the factors associated with the development and prognosis of COVID-19.  It consists of:

  • A data entry interface extracting information from relevant scientific publications
  • A background database containing the key results of the articles entered
  • An algorithm analysing and summarising the results.

Risk assessment tool

The risk assessment tool uses data from the evidence synthesis platform and collects information from users through questionnaires about the presence or absence of symptoms.  An algorithm puts these data together and evaluates the risk of receiving the SARS COV-2 infection, developing COVID-19, and progressing with the disease.  The users receive the estimated risk and possible outcomes based on the most up-to-date information on the COVID-19.

Epidy Health Research Ltd is designing separate interfaces for use by the general public and use by healthcare professionals.

If you can offer legal support, please contact Epidy Health Research Ltd.

For more information please contact
Endre Szigethy

| |
Contact

ASK: Research contributors needed for CON-VICE study

ASK: Research contributors needed for CON-VICE study

University of Luxembourg needs European researchers to get in touch

Find out more

OFFER: Funding available for COVID-19 research

OFFER: Funding available for COVID-19 research

Fondation Air Liquide are looking to fund European projects

Find out more

ASK: Supporting the immunocompromised

ASK: Supporting the immunocompromised

Partners sought to advance neutralising antibody

Find out more